The safety of treatments for angioedema with hereditary C1 inhibitor deficiency

Bibliography

• Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the hereditary angioedema international working group. Allergy 2014;69:602-16
   PubMed Web of Science ®Google Scholar
• Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angio-oedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114:S51-131
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Arcoleo F, Barca M, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis 2015;10-11
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 2002;347:621-2
   PubMed Web of Science ®Google Scholar
• Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009;15:69-78
   PubMed Web of Science ®Google Scholar
• Loghurst H, Cicardi M. Hereditary angio-edema. Lancet 2012;379:474-81
   PubMed Web of Science ®Google Scholar
• Wu MA, Zanichelli A, Mansi M, et al. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency. Expert Opin Pharmacother 2013;14(5):571-86
   PubMed Web of Science ®Google Scholar
• Cicardi M, Mannucci PM, Castelli R, et al. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate.Transfusion. 1995;35:209-12
   Google Scholar
• De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003;29:247-54
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Nanofiltered human C1 inhibitor concentrate (Cinryze®): in hereditary angioedema. BioDrugs 2011;25:317-27
   PubMed Web of Science ®Google Scholar
• Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy 2014;6:533-51
   PubMed Web of Science ®Google Scholar
• EMEA. CPMP/BWP/269/95 rev. 3–Note for guidance on plasma-derived medicinal products. January 25, 2001;EMA
   Google Scholar
• EMA/CHMP/BWP/706271/2010–Guideline on plasma-derived medicinal products. July 21, 2011
   Google Scholar
• FDA. Code of Federal Regulations Title 29pè’, Volume 7, Part 640.Additional standards for human blood and blood products. April 1, 2011
   Google Scholar
• Gröner A, Nowak T, Schäfer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012;52:2104-12
   PubMed Web of Science ®Google Scholar
• Tateishi J, Kitamoto T, Mohri S, et al. Scrapie removal using Planova® virus removal filters. Biologicals 2001;29:17-25
   PubMed Web of Science ®Google Scholar
• Diez JM, Caballero S, Belda F, et al. Capacity of the manufacturing process of Flebogamma® DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent. Biologicals 2010;38:670-4
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of blood plasma products. 2004. p. 151-224
   Google Scholar
• National Hemophilia Foundation. MASAC Recommendation regarding the use of recombinant clotting factor products with respect to pathogen transmission. 2014 [Last accessed 26 January 2015]
   Google Scholar
• Rocino A, Coppola A, Franchini M, et al. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014;12:575-98
   PubMed Web of Science ®Google Scholar
• Federal Drugs Administration. SOP 420 2013
   Google Scholar
• Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010K;126:821-7e814
   PubMed Web of Science ®Google Scholar
• Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 2014;112:163-169e161
   PubMed Web of Science ®Google Scholar
• Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013;110:295-9
   PubMed Web of Science ®Google Scholar
• Arzneimittelkommission der deutschen ƒrzteschaft: Schwerwiegende Thrombenbildung nach BerinertÆ HS. Dtsch Arztebl International 2000;97:A-1016
   Google Scholar
• Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012;125(9):938e1-7
   Web of Science ®Google Scholar
• Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012;32:902-9
   PubMed Web of Science ®Google Scholar
• Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guidelines. Allergy Asthma Clin Immunol 2014;10:50
   PubMed Web of Science ®Google Scholar
• Reshef A, Zanichelli A, Longhurst H, et al. Elevated D-Dimers in Attacks of Hereditary Angioedema Are Not Associated with Increased Thrombotic Risk. Allergy 2015;70(5):506-13
   PubMed Web of Science ®Google Scholar
• Craig TJ, Bewtra AK, Hurewitz D, et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc 2012;33:354-61
   PubMed Web of Science ®Google Scholar
• Cicardi M, Lorenza C. Zingale, Andrea Zanchelli. A patient with hereditary angioedema who experienced anaphylaxis in response to C1 esterase inhibitor is successfully treated with DX-88 (Ecallantide), a potent human plasma kallikrein inhibitor: A case study. Mol Immunol 2007;44:160-1
   Web of Science ®Google Scholar
• Hack CE, Mannesse M, Baboeram A, et al. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. BioDrugs 2012;26:303-13
   PubMed Web of Science ®Google Scholar
• Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012;42:929-35
   PubMed Web of Science ®Google Scholar
• Li HH, Moldovan D, Bernstein JA, et al. Recombinant Human-C1 Inhibitor is Effective and Safe for Repeat Hereditary Angioedema Attacks. J Allergy Clin Immunol Pract 2015;3(3):417-23
   PubMed Web of Science ®Google Scholar
• Hack CE, Relan A, Baboeram A, et al. Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IgE antibodies. Clin Drug Investig 2013;33:275-81
   PubMed Web of Science ®Google Scholar
• Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41
   PubMed Web of Science ®Google Scholar
• Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011;107:529-37
   PubMed Web of Science ®Google Scholar
• CHMP assessment report for Firazyr. Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency. 2008. Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/firazyr/H-899-eu6.pdf
   Google Scholar
• Baş M, Greve J, Hoffmann TK, et al. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study. Allergy 2013;68:1452-9
   PubMed Web of Science ®Google Scholar
• Aberer W, Maurer M, Reshef A, et al. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 2014;69:305-14
   PubMed Web of Science ®Google Scholar
• Malbrán A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol 2014;177:544-53
   PubMed Web of Science ®Google Scholar
• Firazyr® (icatibant), summary of product characteristics. Shire plc., St Helier, Jersey
   Google Scholar
• Yao Y, Sheng Z, Li Y, et al. Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity. Hum Gene Ther 2012;23:859-70
   PubMed Web of Science ®Google Scholar
• Kränkel N, Kuschnerus K, Müller M, et al. Novel insights into the critical role of bradykinin and the kinin B2 receptor for vascular recruitment of circulating endothelial repair-promoting mononuclear cell subsets: alterations in patients with coronary disease. Circulation 2013;127:594-603
   PubMed Web of Science ®Google Scholar
• Thornton E, Ziebell JM, Leonard AV, Vink R. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules 2010;15:6598-618
   PubMed Web of Science ®Google Scholar
• Göb E, Reymann S, Langhauser F, et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann Neurol 2015;77:784-803
   PubMed Web of Science ®Google Scholar
• Danielisova V, Gottlieb M, Bonova P, et al. Bradykinin postconditioning ameliorates focal cerebral ischemia in the rat. Neurochem Int 2014;72:22-9
   PubMed Web of Science ®Google Scholar
• Bovenzi V, Savard M, Morin J, et al. Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli. J Cell Physiol 2010;222:168-76
   PubMed Web of Science ®Google Scholar
• Kalbitor® (ecallantide), package insert. Dyax Corp., MA, USA
   Google Scholar
• Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:523-9
   PubMed Web of Science ®Google Scholar
• Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-31
   PubMed Web of Science ®Google Scholar
• Sheffer AL, Campion M, Levy RJ, et al. Ecallantide(DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double blind, Phase 3 studies. J Allergy Clin Immunol 2011;128:153-159e4
   PubMed Web of Science ®Google Scholar
• Craig TJ, Li HH, Riedl M, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract 2015;3:206-12e4
   Google Scholar
• Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67(2):147-57
   PubMed Web of Science ®Google Scholar
• Berinert® (C1 esterase inhibitor, human) [summary of product characteristics]. CSL Behring
   Google Scholar
• Cinryze® (C1 esterase inhibitor [human]) [summary of product characteristics]. ViroPharma, Incorporated
   Google Scholar
• Ruconest® (conestat alfa) [summary of product characteristics]. Leiden, The Netherlands. Pharming Group NV
   Google Scholar
• Levi M, Choi G, Picavet CJ, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. Allergy Clin Immunol 2006;117(4):904-8
   Google Scholar
• Hernández Fernandez de Rojas D, Ibañez E, Longhurst H, et al. Treatment of HAE attacks in the icatibant outcome survey: an analysis of icatibant self-administration versus administration by health care professionals. Int Arch Allergy Immunol 2015;167(1):21-8
   PubMed Web of Science ®Google Scholar
• Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99:194e196
   Google Scholar
• Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007;120:654-8
   PubMed Web of Science ®Google Scholar
• Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153-61
   PubMed Web of Science ®Google Scholar
• Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol 2015;114:281-8e287
   PubMed Web of Science ®Google Scholar
• Hosea SW, Santaella ML, Brown EJ, et al. Long term therapy of hereditary angioedema with danazol. Ann Intern Med 1980;93:809e812
   Google Scholar
• Zurlo JJ, Frank MM. The long-term safety of danazol in women with hereditary angioedema. Fertil Steril 1990;54:64-72
   PubMed Web of Science ®Google Scholar
• Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981;68:181e187
   Web of Science ®Google Scholar
• Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991;87:768e773
   Web of Science ®Google Scholar
• Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99:194e196
   Google Scholar
• Széplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005;115:864e869
   Web of Science ®Google Scholar
• Birjmohun RS, Kees Hovingh G, Stroes ES, et al. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Clin Ther 2008;30:2314e2323
   Web of Science ®Google Scholar
• Szegedi R, Szeplaki G, Varga L, et al. Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients. Atherosclerosis 2008;198:184-91
   PubMed Web of Science ®Google Scholar
• Farkas H, Czaller I, Csuka D, et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol 2010;66:419-26
   PubMed Web of Science ®Google Scholar
• Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002;36:707-9
   PubMed Web of Science ®Google Scholar
• Crampon D, Barnoud R, Durand M, et al. Danazol therapy: an unusual aetiology of hepatocellular carcinoma [letter]. J Hepatol 1998;29:1035-6
   PubMed Web of Science ®Google Scholar
• Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999;353:1066e1067
   Web of Science ®Google Scholar
• Thoufeeq MH, Ishtiaq J, Abuzakouk M. Danazol-induced hepatocellular carcinoma in a patient with hereditary angioedema. J Gastrointest Cancer 2012;43(Suppl 1):S280eS282
   Google Scholar
• Rahal S, Gilabert M, Ries P, et al. Hepatocellular carcinoma in a noncirrhotic liver after long-term use of danazol for hereditary angioedema. Case Rep Oncol 2014;7:825-7
   PubMedGoogle Scholar
• Pedrosa M, Caballero T, Gómez-Traseira C, et al. Usefulness of abdominal ultrasonography in the follow-up of patients with hereditary C1-inhibitor deficiency. Ann Allergy Asthma Immunol 2009;102:483e486
   Google Scholar
• Cicardi M, Bergamaschini L, Tucci A, et al. Morphologic evaluation of the liver in hereditary angioedema patients on long-term treatment with androgen derivatives. J Allergy Clin Immunol 1983;72:294e298
   Web of Science ®Google Scholar
• Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 2004;114:629-37
   PubMed Web of Science ®Google Scholar
• Santaella ML, Martinó A. Hereditary and acquired angioedema: experience with patients in Puerto Rico. P R Health Sci J 2004;23:13e18
   Google Scholar
• Andriole GL, Brickman C, Lack EE, et al. Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema. J Urol 1986;1351:44e46
   Google Scholar
• Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972;286:808-12
   PubMed Web of Science ®Google Scholar
• Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972;287:452-4
   PubMed Web of Science ®Google Scholar
• Kleniewski J, Blankenship DT, Cardin AD, Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992;120:129-39
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011;66:192-6
   PubMed Web of Science ®Google Scholar
• Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol 2014;10:50
   PubMed Web of Science ®Google Scholar
• Zanichelli A, Mansi M, Periti G, Cicardi M. Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency. Expert Rev Clin Immunol 2013;9:477-88
   PubMed Web of Science ®Google Scholar
• Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24
   PubMedGoogle Scholar
• Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005-32
   PubMed Web of Science ®Google Scholar
• Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001;86:714-15
   PubMed Web of Science ®Google Scholar
• Lindoff C, Rybo G, Astedt B. Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thromb Haemost 1993;70:238-40
   PubMed Web of Science ®Google Scholar
• Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886
   PubMed Web of Science ®Google Scholar
• Uozaki Y, Watanabe G, Kotou K, et al. Effect of tranexamic acid on blood loss reduction after cardiopulmonary bypass. Jpn J Thorac Cardiovasc Surg 2001;49:273-8
   PubMedGoogle Scholar
• Günaldi M, Helvaci A, Yildirim ND, et al. Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation. Cardiol J 2009;16:458-61
   PubMed Web of Science ®Google Scholar
• Sundström A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case–control study using the General Practice Research Database. BJOG 2009;116:91-7
   PubMed Web of Science ®Google Scholar
• Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308-20
   PubMed Web of Science ®Google Scholar
• Sanhueza PI. Contraception in hereditary angioedema. Fertil Steril 2008;90:2015e21-2
   Web of Science ®Google Scholar
• McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci 2000;320:212-13
   PubMed Web of Science ®Google Scholar
• ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update 2009;15:265-77
   PubMed Web of Science ®Google Scholar
• Baker J, Riedl M, Banerji A, et al. Treatment or prophylaxis of acute attacks of hereditary angioedema (HAE) in pregnant subjects Poster 2312. WAO International Scientific Conference; 5 – 8 December 2010; Dubai, UAE
   Google Scholar
• Baker JW, Craig TJ, Riedl MA, et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy Asthma Proc 2013;34(2):162-9
   PubMed Web of Science ®Google Scholar
• Kullander S, Nilsson IM. Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand 1970;49:241-2
   PubMed Web of Science ®Google Scholar
• Gorman PJ. Hereditary angioedema and pregnancy: a successful outcome using C1 esterase inhibitor concentrate. Can Fam Physician 2008;54:365-6
   PubMed Web of Science ®Google Scholar
• Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 2013;162:1017-22
   PubMed Web of Science ®Google Scholar
• Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012;52:100-7
   PubMed Web of Science ®Google Scholar
• Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124:801-8
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22
   PubMed Web of Science ®Google Scholar
• Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007;120:e713-22
   PubMed Web of Science ®Google Scholar